Financial Data and Key Metrics Changes - For Q3 2025, organic net sales declined by 4.4%, impacted by a 1.6% decline from the global OTC business and a 2.8% decline from businesses under review [11][12] - Year-to-date, organic net sales decreased by 1.7%, primarily driven by a 0.8% impact from businesses under review and a 0.5% impact from the absence of last year's Opill launch stocking benefits [12][24] - Q3 EPS was $0.80, down one cent from the prior year, while year-to-date EPS grew 21% to $1.97 [11][21] Business Line Data and Key Metrics Changes - In the US OTC market, Perrigo gained volume share of 90 basis points across nearly every category, particularly in smoking cessation, allergy, and women's health [6][13] - The CSCI segment saw a 5.3% decline in organic net sales for Q3, primarily due to soft OTC category consumption trends, while year-to-date organic net sales grew by 0.7% [19][20] - The infant formula business experienced a 3.8% decline in Q3, with share recovery taking longer than expected [14][20] Market Data and Key Metrics Changes - US OTC volume consumption declined by 3.2%, while European OTC grew by only 0.6%, falling short of original assumptions [13][24] - The overall market consumption trends have been softer than anticipated, impacting Perrigo's net sales outlook by an estimated $150-$170 million [13][24] Company Strategy and Development Direction - The company is focused on its 3S plan: stabilize, streamline, and strengthen, which has guided its actions and priorities [8][16] - A strategic review of the infant formula business is underway, with the aim to optimize its long-term role within the Perrigo portfolio [14][47] - The sale of the dermocosmetics business is on track to close in Q1 2026, with proceeds aimed at reducing leverage [23][47] Management's Comments on Operating Environment and Future Outlook - Management noted that the current consumption trends are dynamic and unpredictable, with expectations for stabilization in 2026 [41][46] - The company remains committed to deleveraging and sustaining dividends while focusing on high-potential OTC portfolio growth [15][47] - Management expressed confidence in Perrigo's ability to capture durable demand for consumer health solutions despite current challenges [17][46] Other Important Information - The company has achieved $163 million in gross annual savings from Project Energize, exceeding initial expectations [9][18] - Operating cash flow for Q3 was $52 million, with year-to-date cash flow at $63 million [22][23] Q&A Session Summary Question: Follow-up on infant formula share and expectations - Management acknowledged that while store brand share is growing, it is at a slower pace than anticipated due to competitive pressures and market dynamics [28][29] Question: Insights on OTC and infant formula consumption changes - Management noted that OTC consumption has been volatile, with a significant decline observed in Q3 compared to previous quarters [33][34] Question: Plans for reinvestment given current market conditions - Management indicated that while priorities remain on deleveraging and maintaining dividends, there may be opportunities to increase spending in high-performing areas [38][39] Question: Current share of infant formula and future growth expectations - Management reported an approximate 16% share in infant formula, with expectations to grow to 18-20% over the next 12 months [40][41] Question: Clarification on gross margin pressure - Management confirmed that the gross margin pressure was primarily due to sales deleverage and product mix, not input costs [42][43]

Financial Data and Key Metrics Changes - Perrigo's organic net sales growth in Q2 2025 was flat compared to the prior year, with OTC brand growth of 3.6% [8][10] - Gross margin declined by 250 basis points, impacted by divested businesses and isolated production variability in infant formula [11][30] - EPS in the quarter grew by 7.5% or 12.5% organically, with year-to-date EPS growth exceeding 50% organically [12][34] Business Line Data and Key Metrics Changes - The infant formula business net sales grew by 9%, driven by store brand formula, while the Good Start brand experienced a significant decline due to lost distribution [6][16] - Pain and sleep aids grew by 8%, contributing positively to overall growth, while the digestive health category faced challenges due to lower consumption of proton pump inhibitors [12][14] - OTC brands delivered organic net sales growth of 3.6%, with Jungle Formula and Compie achieving significant market share gains [13][14] Market Data and Key Metrics Changes - Store brands are gaining share in volume and unit share as consumers seek value amidst economic uncertainty [10][12] - The U.S. market is experiencing declining total category consumption, while the EU is seeing decelerating consumption trends [10][11] - Perrigo's allergy product sales at a key retailer increased by almost 19% year-to-date, contrasting with a category decline of over 2% [19] Company Strategy and Development Direction - The company is focused on its 3S plan: Stabilize, Streamline, and Strengthen, with significant progress made in stabilizing the infant formula business and streamlining operations [5][26] - An agreement to sell the derma cosmetics business for up to EUR 327 million is expected to sharpen strategic focus on core high-growth brands [6][21] - The company aims to enhance its category-led market activation growth model to unlock portfolio potential and improve execution [22][23] Management's Comments on Operating Environment and Future Outlook - Management described the market as fluid and volatile, with heavy promotional activity from competitors impacting share growth expectations [44][45] - Despite challenges, the company remains confident in achieving its EPS target range of $2.9 to $3.1 per share, equating to strong double-digit growth [38][88] - Management acknowledged the slower-than-expected recovery in the infant formula business but emphasized ongoing demand generation efforts [46][84] Other Important Information - Year-to-date organic gross profit increased by 3.8%, primarily due to recovery in the infant formula business [31] - The company is on track to deliver a full-year gross margin of approximately 40% [30] - Operating cash flow for the year to date was $11 million, with cash on the balance sheet at $454 million [35][36] Q&A Session Summary Question: Insights on the infant formula market and competitor responses - Management noted that the market is fluid, with brands heavily promoting to gain share, and acknowledged that their shelf placement is not optimal at certain retailers [44][45] Question: Building blocks for achieving guidance in the second half - Management confirmed that the EPS requirement for the second half aligns with guidance, emphasizing confidence in OTC store brand growth and infant formula recovery [49][52] Question: Strategic pricing actions and retailer conversations - Management indicated that discussions with retailers regarding pricing are positive, with expectations to offset tariff impacts through pricing actions and supply chain adjustments [61][62] Question: Changes in expectations for Opill and marketing plans - Management expressed satisfaction with Opill's performance, noting double consumption growth and plans to continue investing in brand awareness [72][74] Question: Increased product scrap in infant formula and future confidence - Management clarified that the increased product scrap was an isolated issue caught by quality systems, and they are confident it will not continue to impact margins [80][82]

Summary of Perrigo Company (PRGO) FY Conference - June 10, 2025 Company Overview - Perrigo is a global leader in the self-care market, holding over 50% of the US store brand share and ranking among the top 10 branded companies in Europe [4][5] - The company offers a diverse range of products across various price points, catering to different economic cycles and consumer habits [5][6] Core Business Strategy - Perrigo's strategy is anchored on three imperatives: stabilize, streamline, and strengthen [6][7] - The focus is on returning the US store brand to growth, ensuring reliable quality in infant formula supply, and driving innovation in high-growth brands [7][8] - The company aims for incremental revenue growth of $100 to $200 million by 2027, with a target of reducing net leverage below three times by the end of the year [8][12] Market Position and Performance - Perrigo's portfolio is diversified, with 40% of sales from branded products and 60% from store brand contributions [8][9] - The company is the largest OTC manufacturer by volume in the US and UK, with products present in nearly two-thirds of US households and over 80% of UK households [9][10] - Recent store brand volume share in the US increased by 110 basis points in May, indicating strong market performance [14] Financial Outlook - The company is trading at a significant discount compared to consumer health peers, presenting a value opportunity [11] - Expected double-digit adjusted EPS growth in 2025, with a high single-digit PE multiple [15] - Plans to improve free cash flow to net sales ratio by 200 basis points over three years, focusing on inventory optimization and operational efficiency [55][56] Challenges and Opportunities - The macro environment remains fluid, with pressures on consumer spending affecting OTC categories [13][29] - Trade-down behavior is observed in various categories, but Perrigo's position as a store brand provider offers a defensive advantage [13][29] - The infant formula business is recovering, with plans to launch 60 new SKUs to enhance market share [40][41] Regulatory and Tariff Considerations - The company anticipates a 1% increase in COGS due to tariffs, amounting to approximately $35 million in 2025 [48] - Ongoing strategic reviews of the oral care and derma cosmetic businesses to optimize portfolio focus [51][53] Conclusion - Perrigo is well-positioned to leverage its unique market position and diversified portfolio to drive growth and shareholder value, while navigating challenges in the consumer landscape and regulatory environment [22][54]

Financial Data and Key Metrics Changes - Organic net sales declined by 0.4%, but excluding lost distribution and prior year effects, organic net sales grew by 1.8% year over year [16][25] - Gross margin expanded by 440 basis points year over year to 41%, driven by business recovery in infant formula [16][25] - First quarter EPS increased by 107% year over year to $0.60 per share [16][28] Business Line Data and Key Metrics Changes - Infant formula net sales increased by 19% compared to the same quarter last year, contributing to overall recovery [7][19] - OTC brands achieved solid organic growth of 5.9% year over year, driven by strong sales of key products [10] - Operating income in the CSCI segment grew by 10% organically, while CSEA operating income grew by 90% due to infant formula recovery [27] Market Data and Key Metrics Changes - Dollar sales across self-care categories turned negative compared to the prior year, reflecting cautious consumer behavior due to inflation and reduced consumer confidence [11][12] - Total US OTC store brand volume gained 50 basis points over the last four weeks, indicating a shift in consumer buying patterns towards value-oriented products [15] Company Strategy and Development Direction - The company is focused on its 3S plan: stabilize, streamline, and strengthen, with positive results from stabilizing key parts of the business [6][21] - The synergistic relationship between store brand and OTC brands is being leveraged to drive growth, with substantial cash flow generated from store brands [10] - The company is enhancing its new product development process to create a more efficient pipeline [11] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the uncertain macroeconomic environment but expressed confidence in the company's positioning to navigate these challenges [12][22] - The company is widening its 2025 net sales projections due to macroeconomic uncertainties while reaffirming its adjusted EPS range [12][30] - Management expects a significant ramp-up in infant formula sales in the second half of the year due to new product introductions [39] Other Important Information - The company plans to offset tariff-related cost increases through strategic pricing actions and sourcing more manufacturing to US facilities [14][30] - The gross increase in global cost of goods sold from tariffs is expected to be approximately 5.5% for the full year [32] Q&A Session Summary Question: Impact of tariffs on EPS for 2026 - Management expects that actions taken to mitigate tariff impacts will offset any major changes in EPS projections for 2025 and beyond [36][37] Question: Sales ramp for infant formula - Management anticipates a similar sales trajectory in Q2, with significant growth expected in the second half due to new SKU introductions [38][39] Question: Contract manufacturing activity - There is an increase in activity for contract manufacturing as competitors seek domestic supply routes [44] Question: Organic sales performance - Organic sales were broadly in line with expectations, with upper respiratory products performing well despite some regional variances [48][49] Question: Gross margin expectations - Management maintains a full-year gross margin expectation of around 40%, despite better-than-expected Q1 performance [52][53] Question: Widening net sales range - The widening range reflects dynamic shifts in consumer behavior and ongoing opportunities in the market [60][62] Question: Pharma-specific tariffs impact - Management anticipates a potential $100 million impact from pharma-specific tariffs, with plans to mitigate through pricing and sourcing strategies [84][85]